Do LDLR-reducing variants or absence of PCSK9 loss-of-function protection impair hepatic LDL clearance and raise LDL cholesterol?

The claim that variants reducing LDL receptor (LDLR) function or reducing protective PCSK9 loss-of-function variants impair hepatic LDL clearance and elevate blood levels of LDL cholesterol is fully supported by established genetic and physiological evidence.

Molecular and physiological mechanisms

• LDLR-Mediated Clearance: The low-density lipoprotein receptor (LDLR) on hepatocyte membranes binds circulating LDL particles to internalize them via endocytosis. Pathogenic variants in the LDLR gene disrupt receptor folding, endoplasmic reticulum trafficking, or ligand binding. This reduces active receptor density at the cell surface, directly impairing the hepatic clearance of LDL particles.
• PCSK9 Regulation: Under normal (wild-type) conditions, active PCSK9 binds to LDLR and targets it for lysosomal degradation rather than recycling. This limits the number of receptors available for clearing LDL.
• Lack of Loss-of-Function Protection: PCSK9 loss-of-function (LOF) variants (e.g., R46L) prevent this receptor degradation, thereby preserving high LDLR density on hepatocytes. When an individual lacks these protective LOF variants, wild-type PCSK9 activity proceeds unrestricted, leading to lower hepatocyte LDLR density and impaired clearance of LDL particles.

Clinical and genetic evidence

• Familial Hypercholesterolemia (FH): Genetic variants that reduce LDLR function are the hallmark of heterozygous and homozygous FH. The severity of circulating LDL cholesterol (LDL-C) elevation directly correlates with the functional defect of the variant; individuals with homozygous null mutations show minimal clearance and severely elevated LDL-C.
• PCSK9 Genetic Effects: Large-scale cohort studies demonstrate that individuals possessing protective PCSK9 LOF variants (such as R46L) have significantly lower lifetime circulating LDL-C. Conversely, carrying wild-type PCSK9 (lacking the LOF protection) results in higher steady-state LDL-C levels, typically by 25 to 35 mg/dL.
• Cardiovascular Risk: Long-term cardiovascular outcomes show that the elevated LDL-C resulting from these clearance bottlenecks is causally linked to an increased lifetime risk of coronary artery disease and cardiovascular events.

Bottom line

Genetic variants that reduce LDLR expression or function, or that lead to standard PCSK9-mediated LDLR degradation (by lacking protective PCSK9 loss-of-function variants), directly impair the liver's capacity to clear LDL particles. This clearance defect leads to a sustained, clinically significant increase in circulating LDL cholesterol.